» Articles » PMID: 32275288

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Overview
Journal JAMA Neurol
Date 2020 Apr 11
PMID 32275288
Citations 3663
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.

Objective: To study the neurologic manifestations of patients with COVID-19.

Design, Setting, And Participants: This is a retrospective, observational case series. Data were collected from January 16, 2020, to February 19, 2020, at 3 designated special care centers for COVID-19 (Main District, West Branch, and Tumor Center) of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. The study included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection.

Main Outcomes And Measures: Clinical data were extracted from electronic medical records, and data of all neurologic symptoms were checked by 2 trained neurologists. Neurologic manifestations fell into 3 categories: central nervous system manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscular injury manifestations.

Results: Of 214 patients (mean [SD] age, 52.7 [15.5] years; 87 men [40.7%]) with COVID-19, 126 patients (58.9%) had nonsevere infection and 88 patients (41.1%) had severe infection according to their respiratory status. Overall, 78 patients (36.4%) had neurologic manifestations. Compared with patients with nonsevere infection, patients with severe infection were older, had more underlying disorders, especially hypertension, and showed fewer typical symptoms of COVID-19, such as fever and cough. Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 [2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]).

Conclusions And Relevance: Patients with COVID-19 commonly have neurologic manifestations. During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.

Citing Articles

Rapid generation and characterization of recombinant HCoV-OC43-VR1558 infectious clones expressing reporter Renilla luciferase.

Ye F, Wang N, Guan Q, Wang M, Sun J, Zhai D Biosaf Health. 2025; 6(6):350-360.

PMID: 40078980 PMC: 11894994. DOI: 10.1016/j.bsheal.2024.11.006.


Nucleocapsid Protein of SARS-CoV-2 Upregulates RANTES Expression in A172 Glioblastoma Cells.

Gadilgereyeva B, Kunushpayeva Z, Abdrakhmanova M, Khassenova A, Minigulov N, Burster T Molecules. 2025; 30(5).

PMID: 40076291 PMC: 11902235. DOI: 10.3390/molecules30051066.


Prion propensity of Betacoronaviruses including SARS-CoV-2.

Haddad H, Al-Zyoud W Heliyon. 2025; 11(4):e42199.

PMID: 40034268 PMC: 11874563. DOI: 10.1016/j.heliyon.2025.e42199.


Editorial: NeuroCOVID. Insights into the clinical manifestations and pathophysiology.

Gonzalez-Quevedo A, Valdes Sosa P, Machado Curbelo C, Gutierrez Gil J Front Neurol. 2025; 16:1561314.

PMID: 40007741 PMC: 11852433. DOI: 10.3389/fneur.2025.1561314.


SARS-CoV-2: A synergy to the Alzheimer's disease.

Shaik K, Kumar D, Srikanth P, Nandi S J Neurovirol. 2025; .

PMID: 39998800 DOI: 10.1007/s13365-025-01247-w.


References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

3.
Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J . Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004; 203(2):622-30. PMC: 7167761. DOI: 10.1002/path.1560. View

4.
Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K . Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67. PMC: 6812437. DOI: 10.1164/rccm.201908-1581ST. View

5.
Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H . Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2):631-7. PMC: 7167720. DOI: 10.1002/path.1570. View